Healthy volunteers key to safer stem cell transplants
NCT ID NCT00001529
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 6 times
Summary
This study collects blood stem cells from healthy volunteers after they receive a growth factor injection. Researchers aim to develop better methods to remove the white blood cells that cause graft-versus-host disease, a serious complication of bone marrow transplants. Up to 500 volunteers aged 18-60 will participate to help improve transplant safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- filgrastim (G-CSF)
- What this could lead to
- If successful, this could lead to safer stem cell transplants with less risk of graft-versus-host disease.
- What could go wrong
- This is an early-stage lab study, not a treatment trial. Results may not translate to better patient outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DONOR APHERESIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug tame graft-versus-host disease when steroids fail?
- New antibody may offer safer shield against transplant complications
- New drug combo aims to tame immune attack after stem cell transplants
- New drug cocktail aims to stop transplant rejection in blood cancer patients
- New eye drops aim to soothe dry eye in bone marrow transplant patients
- Donor stem cell transplant shows promise for tough blood cancers